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Accumulating Data to Optimally Predict Obesity Treatment
(ADOPT): Recommendations from the Biological Domain
Michael Rosenbaum 1, Tanya Agurs-Collins2, Molly S. Bray3, Kevin D. Hall 4, Mark Hopkins5, Maren Laughlin4,
Paul S. MacLean6, Padma Maruvada6, Cary R. Savage7, Dana M. Small8, and Luke Stoeckel4

Background: The responses to behavioral, pharmacological, or surgical obesity treatments are highly
individualized. The Accumulating Data to Optimally Predict obesity Treatment (ADOPT) project provides a
framework for how obesity researchers, working collectively, can generate the evidence base needed to
guide the development of tailored, and potentially more effective, strategies for obesity treatment.
Objectives: The objective of the ADOPT biological domain subgroup is to create a list of high-priority biological measures for weight-loss studies that will advance the understanding of individual variability in
response to adult obesity treatments. This list includes measures of body composition, energy homeostasis
(energy intake and output), brain structure and function, and biomarkers, as well as biobanking procedures,
which could feasibly be included in most, if not all, studies of obesity treatment. The recommended highpriority measures are selected to balance needs for sensitivity, specificity, and/or comprehensiveness with
feasibility to achieve a commonality of usage and increase the breadth and impact of obesity research.
Significance: The accumulation of data on key biological factors, along with behavioral, psychosocial,
and environmental factors, can generate a more precise description of the interplay and synergy among
them and their impact on treatment responses, which can ultimately inform the design and delivery of
effective, tailored obesity treatments.
Obesity (2018) 26, S25–S34. doi:10.1002/oby.22156

Introduction
Weight loss provokes coordinated changes in multiple energy
homeostatic systems which culminate in disproportionately increased
energy intake (EI) and decreased energy expenditure (EE) (1,2). The
extensive interindividual variability in responses to weight loss (3)
and treatments differentially targeting these systems (4,5) suggests
that treatment could be improved via better understanding of the
biological factors mediating energy balance (6,7).
The NIH-sponsored Accumulating Data to Optimally Predict obesity
Treatment (ADOPT) Core Measures Project (8) aims to advance
adult obesity medicine in the face of this individual variability in
treatment responses (9). ADOPT is designed to provide investigators
with tools to generate an evidence base consisting of common measures across the following four domains: behavioral, biological,

environmental, and psychosocial, which can enhance interdisciplinary research and advance understanding of the sources of response
variability, depicted in the ADOPT Working Model.
The biological domain subgroup of the ADOPT working group was
tasked with recommending core measures relevant to the “constructs”
of body composition, energy balance, biomarkers, brain structure and
function, and biobanking, as previously designated by the full ADOPT
working group. The uniform reporting of common measures can
increase the impact and generalizability of the combined research
body. Further information regarding each construct and measure
described below is available at the ADOPT Core Measures Workspace
in the Grid-Enabled Measures (GEM) database (https://www.gemmeasures.org/workspaces/ADOPT), which is also a venue for discussions that help to build consensus around common measures.
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Identification of Biological Measures
In an effort to create a list of measures of relevant biological constructs that could be employed across most, if not all, clinical human
obesity studies, several factors were considered in the selection of
the methods (designated as “measures”) best designed to evaluate
each construct given the constraints of human weight-loss trials.
These included (1) the strength of the current evidence relating each
measure to relevant constructs and weight-loss outcomes, (2) the
measure’s validity and reliability, (3) the feasibility of widespread
use of the measure, (4) the measure’s burden to investigators (cost,
administration, availability) and subjects (time and invasiveness),
and (5) the measure’s applicability to small (<50 participants), moderate (50-200 participants), and large (>200 participants) studies.
In many cases, the “gold standard” measures were not the most
practical within the feasibility constraints of many weight-loss trials.
Recognizing the frequent dichotomy between precision and practicality, we provide two classifications of measures within the constructs. “Recommended” measures are those that should be feasible
and cost-effective in all obesity-related clinical trials. “Suggested”
measures are those that should be feasible and cost-effective in
many, if not most, clinical trials and, if possible, should be performed in addition to the recommended measures. Except as otherwise noted (e.g., for targeted genetic studies), all measures outlined
below should be obtained at baseline and at other time points (e.g.,
during and after an intervention) in each study.

Body Composition
Within the area of body composition, we included both anthropometric and bioelectrical impedance measures to allow for the assessment of body fat content, central versus peripheral fat distribution,
and visceral versus subcutaneous fat distribution in a manner that
can be integrated across previous and future studies (10). It is likely
that this recommendation will change going forward, as more investigators use recommended measures of body fat content (see below).

Anthropometry
Anthropometry includes the assessment of height, weight, and calculated BMI (recommended) as well as central fat mass (FM) and the
relative distribution of fat in central and peripheral fat depots by
waist and hip circumferences and calculated waist-to-hip ratio
(WHR) (recommended). The feasibility of anthropometry permits
easy frequent measurement (at least every 1 to 3 months in the initial phases of weight-loss trials), which is necessary to document
early responses (1 to 2 months) to surgical (11,12) and nonsurgical
(13,14) interventions as predictors of long-term success.
However, together BMI, sex, and age only explain approximately
50% to 60% of the variance in percent body fat as measured by dual
energy x-ray absorptiometry (DXA) (suggested), which is the “gold
standard” (15), and anthropometry is clearly less accurate than bioelectric impedance spectroscopy (BIS), DXA, magnetic resonance
imaging (MRI), and BodPod (see below). The accuracy of BMI is further diminished in participants with increased fractional lean body
mass, such as athletes with very high muscle mass, (e.g., weightlifters)
(16), or increased fractional FM, such as the elderly. BMI does not
assess FM and fat-free mass (FFM), both of which are important
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determinants of EE and EI, and different interventions may differentially affect body composition (FM and FFM) and weight (16).
It is recommended that both waist circumference and WHR are collected in all adult studies (17) because both the absolute amount of
central fat (17,18) and the relative amount of fat distributed in central versus peripheral fat depots (19,20) have been shown to be predictive of multiple adiposity-related comorbidities and may affect
intervention response (21-23). Both of these measures have been
reported to correlate closely with visceral and subcutaneous adipose
tissue measured by DXA (suggested) or MRI (24,25). To minimize
variability in WHR, it is critical that investigators utilize uniform
landmarks, with waist circumference measured at the iliac crest and
hip circumference measured at the level of the trochanters as utilized by the National Center for Health Statistics in National Health
and Nutrition Examination Survey studies (26). It should be noted
that the abdominal circumference measured at the midpoint between
the inferior border of the ribcage and the superior aspect of the iliac
crest has been reported to be a better correlate of central adiposity
in some studies (27). However, the NIH method is recommended to
allow for better comparisons with existing National Health and
Nutrition Examination Survey and other data.

Anatomic fat storage
Anthropometry fails to distinguish subcutaneous from visceral fat,
which has been reported to be correlated with the risk for metabolic
syndrome, cardiovascular disease, and several malignancies (28), and
the relative distribution of visceral and subcutaneous fat varies significantly by gender and between ethnic and/or racial groups (29). Specifically, it is recommended that all studies include more direct measures
of FM by BIS (30), which is a noninvasive and inexpensive type of
bioimpedance to assess body composition that can be utilized in studies of any size or duration. BIS is comparable with the singlefrequency devices used in bioimpedance analysis (conventionally
denoted as BIA) in terms of subject burden and cost. The multisegmental, multifrequency BIS device allows for the identification of
more components of bioimpedance (capacitance, resistance, etc.) than
single-frequency bioimpedance analysis devices, and BIS measures of
extracellular/intracellular resistance have been reported to be significantly correlated with intraabdominal FM measures by computed
tomography scans (31). BIS has also been reported to correlate better
with FM than BMI and with visceral and/or intraabdominal fat (measured by MRI) than waist circumference or WHR (32). Overall, BIS
has been reported to explain 80% to 90% of the variance in FM and
visceral fat and 50% to 55% of the variance in intraabdominal fat by
DXA and/or MRI (32,33). Despite the advantages of BIS, it has been
reported to underestimate FM and overestimate FFM, especially in
males (33), and BIS can be less reliable when the hydration status of
FM and FFM are uncertain (e.g., in children, individuals with edema,
and postbariatric surgery patients). In addition, there are multiple BIS
systems available that have not been crossvalidated. It is therefore
essential to always report the exact BIS system utilized.
The addition of BIS will allow for the integration of data from multiple studies and further validation of this approach. Though BIS
provides the best option for the assessment of body composition,
when balancing the value of the data with the cost and participant
burden in large clinical trials, this recommendation does not preclude the use of more accurate or precise suggested measures of
body composition such as DXA, MRI, or quantitative magnetic

www.obesityjournal.org

Supplement

Obesity

THE ADOPT PROJECT

resonance spectroscopy. It is anticipated that the acquisition of BIS
data along with other suggested measures of body composition in
some studies will provide a large data set that can be utilized to better define the precision of BIS in different populations.

Energy Balance
The relative long-term constancy of body weight and the overall
lack of success of nonsurgical interventions in long-term weight
reduction suggests that, at usual weight, EI and output are “coupled”
and vary directly to maintain energy stores. Once weight is perturbed, this coupling is lost, and EI and energy output now vary
inversely to “defend” previous body energy stores (2,34). There is
large interindividual variability in EI and EE (including cardiorespiratory fitness [CRF], which is an important determinant of exercise
recommendations) and, of course, adherence before, during, and
after weight change (3,23,35-37). A better understanding of this variability is likely to identify certain energy homeostatic phenotypes
that are predictive of individualized best practice recommendations.

EE
Total EE (TEE) is composed of resting EE (REE), the thermic effect
of feeding (TEF), and nonresting EE (NREE) (38), each of which is
likely to change in weight-loss studies. Direct and indirect objective
measures for these variables present challenges for large clinical
weight-loss trials because of their expense, participant burden, and
feasibility. Because of these limitations, it is recommended that
measures of TEE and its components be calculated.
Calculated REE should be acquired with the Mifflin-St. Jeor equation
(recommended) (39), which is best correlated (R2 5 0.80-0.85) with
calorimetric measures of REE (39) and superior to other less-studied
or more population-specific equations (40). The following are the
Mifflin-St. Jeor equations: for males, REE (kilocalories per day)5 10 3 weight (kilograms) 1 6.25 3 height (centimeters) 2 5 3 age
(years) 1 5; for females, REE (kilocalories per day) 5 10 3 weight
(kilograms) 1 6.25 3 height (centimeters) 2 5 3 age (years) 2 161.
It should be noted that the Mifflin-St. Jeor equation may also have
limitations in its generalizability. Equations for individuals who are
transgender, intersex, have abnormal numbers of X or Y chromosomes, or who have undergone or are undergoing surgical or hormonal therapy relevant to gender have not as yet been derived (41).
The increasing attention to gender medicine and gender-specific biological variation in human metabolic disease should yield an
expanded list of calculations going forward.
In lieu of directly measuring NREE, it is recommended that a
questionnaire-based assessment of Physical Activity Level (PAL) be
acquired (42). PAL is defined as TEE/REE, and the questionnairederived PAL was chosen because of its simplicity, its validation by
correlation with PAL measured by calorimetry, and its applicability
across multiple studies. This questionnaire provides a self-evaluation
of physical activity during work and leisure activities. The calculated REE and PAL can then be used to derive a calculated TEE
(TEE 5 PAL 3 REE).

TEE, its components, and metabolic adaptation in response to treatment (43) but are not feasible in many weight-loss trials because of
the expense and required specialized equipment (38,44). If possible,
the calorimetric measurement of REE in the overnight fasted state
by using a metabolic cart or room indirect calorimeter to measure
rates of carbon dioxide production (VCO2) and oxygen consumption
(VO2) is suggested. The VCO2/VO2 ratio provides an index of the
relative mixture of metabolic fuels being utilized. Similarly, doublylabeled water can be used to measure TEE in the free-living environment, and whole-room indirect calorimetry chambers can be used
to provide robust objective estimates of TEE, NREE, and REE.
Though these approaches can also be utilized to acquire TEF with
the appropriate feeding study design, TEF is neither recommended
nor suggested across all studies because of the necessary complexity
of these designs coupled with the relatively small contribution of
TEF to TEE and adaptive thermogenesis (3).

EI
Under static conditions of body weight and composition stability, EI
must be equal to TEE. EI steady state (recommended) refers to EI
when body composition and mass are not changing over time and
can be presumed equal to the calculated TEE (45). It should be
noted that this does not include or account for variations in diet
composition or the possible effects on the partitioning of stored
calories (see the body composition section) that might occur, for
example, as a result of weight loss with a resistance training component (increased partitioning of stored calories as FFM) versus aerobic training (46). During dynamic periods of weight change
(EI 6¼ EE), measuring EI is more difficult. Self-reported EI measures
have been shown to be inaccurate (47) but changes in EI (recommended) during such periods can be mathematically modeled with
measures of EE and body composition dynamics (33). This model
has recently been validated against the intake-balance method in a
2-year calorie-restriction experiment in 140 people of varying age
and BMI (48), and it requires only baseline anthropometric and
demographic information along with repeated body weight measurements over the course of the intervention. There are assumptions
underlying this model, such as the stability of REE and PAL. More
frequent body weight measurement increases the precision of the
calculated changes in EI over time, and physical activity time course
data (e.g., from actigraphy measurements) can also be incorporated
to account for changes in NREE. The full description of this calculation, including MatLab Code information, can be found at the GEM
website (https://www.gem-measures.org/workspaces/ADOPT).
The estimation of the average EI over an extended duration is
ideally calculated by using the intake-balance method involving
body composition measurements along with repeated TEE measurements by using doubly labeled water (49); these procedures are,
unfortunately, impractical for larger weight-loss studies. Depending
upon the duration and types of weight-loss intervention, and participant age and gender, calculated EI based on TEE and weight or
body composition change has accounted for between 20% and 60%
of the variance in EI calculated by using the intake-balance method
(suggested) as described above (48).

CRF
The working group readily acknowledges that other direct and indirect measures can provide more accurate and precise measures of
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responses to obesity treatment either directly or via compliance with
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exercise recommendations (50). CRF is also significantly correlated
with mortality and comorbidity risk, independent of body fatness
(51). Though the gold standard for CRF is an ergometric VO2max
test, an approximation can be made from resting heart rate or an
alternative submaximal fitness test. Resting heart rate was selected
as a recommended measure because it is easy and inexpensive to
perform and has been reported to explain about 20% of the variance
in CRF (52) using multiple different equations and calculations. The
3-minute step test has been reported to explain 50% to 90% of the
variance in fitness by treadmill testing but may not be practical for
larger studies, and it is therefore suggested rather than recommended
(53,54). For subjects who are unable to perform the step test because
of orthopedic or fitness issues, a simpler version using a corridor
walk may be substituted (55).

Brain Structure and Function
Obesity-associated alterations in brain structure and function (56,57)
have been correlated with weight loss and regain in behavioral and
bariatric surgery trials (56,58), with limited data regarding other
treatments. Incentive motivation, reward learning, and executive
function (including working memory) (58) are the neurocognitive
constructs most predictive of treatment outcomes. These functions
are largely mediated by the dopaminergic fronto-striatal (reward/
motivation), fronto-parietal (executive function), and hippocampalamygdala (learning and memory) systems, which operate as both
independent and interdependent networks (59). Emerging data has
also indicated that related neural systems (interoceptive and salience
networks) could be important for weight outcome prediction (60).
This manuscript focuses on brain structure and function rather than
the affected neurocognitive constructs discussed in the ADOPT
psychosocial domain (61). The current gold standard measures are
MRI to assess structure and blood oxygen-dependent functional MRI
(fMRI) to assess function. FMRI can identify the (1) neural substrates that execute behaviors in response to environmental demands
and (2) functionally linked intrinsic neural networks that can be
assessed in the absence of external, environmental demands (i.e.,
resting state fMRI). The measurement of resting-state connectivity is
feasible in large multisite studies and, when integrated with other
measures (e.g., cognitive, psychosocial, other biomarkers), can
define mechanisms and neuropsychological subtypes that may predict responses to treatment (62) even though correlations of restingstate fMRI in specific single brain regions with behaviors are relatively low (63-69).
Because of the cost and burden to both the participants and researchers, resting-state fMRI scans are only suggested when feasible. Analyses of these fMRI data should include the assessment and comparison
across several networks representing the neural systems described
above. The suggested MRI/fMRI protocol includes (1) anatomical
MRI for structure (volume, density, shape, cortical thickness) and to
aid in preprocessing of the fMRI data, (2) diffusion MRI (white matter
tractography or structural connectivity), and (3) resting-state functional connectivity MRI. Given that resting-state functional connectivity MRI may be sensitive to the internal state, collecting data about
the participant’s last meal and the subjective experience of the internal
state (hunger, satiety) is suggested (61). Resting-state studies in fasting and fed states will provide insights into brain areas related to meal
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initiation and cessation. The value of fMRI is significantly increased
through the integration with neurocognitive and psychosocial measures (61) and biomarkers of EI (e.g., gut peptides) and EE (e.g., leptin
and thyroid hormones) described below.

Humoral Biomarkers
Biomarkers can provide information about the potential mechanisms
by which information regarding nutreint availability, energy stores,
and energy balance are communicated to central nervous system
tracts regulating energy homeostasis as well as provide valuable
insights into adiposity-related comorbdities. Biomarker significance
is influenced by whether subjects are at weight homeostasis, are
weight-reduced, or are in the process of weight gain or loss. Some
of the recommended biomarkers (e.g., leptin) predictably and coordinately change in response to calorie-restricted weight loss in a
manner that would elevate appetite and suppress EE (1). Baseline
measures for some recommended biomarkers (e.g., leptin, total ghrelin) are predictive of weight regain (70,71) in some, but not all,
studies (72). The potential value and/or cost of these measures at
baseline, after weight loss, and after a period of weight maintenance
is considered high, given the low subject burden (i.e., a blood draw)
and commercial availability of the assays.

Energy homeostasis
A number of adipocyte-derived hormones yield valuable data
regarding factors that may affect or represent energy stores and balance. As exemplified by leptin (recommended) (73), response to any
intervention may depend upon whether the participant is being
treated to promote weight loss or prevent weight regain. Therefore,
biochemical assessments relevant to energy balance and/or affecting
EI and energy output are extremely relevant.
Leptin is secreted by adipose tissue, reflects both adipose tissue stores
and energy balance, and is recommended. At baseline weight, circulating leptin concentrations are directly proportional to FM, while during
caloric restriction, the leptin/FM ratio may be severely decreased versus only mildly diminished following weight loss (73). A low ratio of
leptin to FM may therefore be an indicator of undernutrition, while an
unusually high ratio may suggest leptin resistance.
The measurement of fasting levels of the pancreatic peptide amylin
is recommended, not only for its effects on nutrient utilization by
inhibition of postprandial glucagon, but also because it reduces EI
by promoting satiation and attenuates the disproportionate decline in
EE that typically occurs during and following weight loss; it thus
serves as a marker of weight response (74). In rodent studies, amylin
receptors are located within the brainstem as well in multiple other
organs, and exogenous amylin acts synergistically with leptin as
well as glucagon-like peptide 1 (GLP-1), peptide YY (PYY3-36), and
other anorexiant molecules (75). In human studies, coadministration
of amylin with leptin has been shown to enhance weight loss during
caloric restriction (76).
Adiponectin, particularly high-molecular-weight (HMW) adiponectin, is recommended because of its positive association with cardiovascular fitness and insulin sensitivity and its negative association
with the secretion of multiple proinflammatory cytokines. During
caloric restriction, adiponectin levels increase disproportionately to
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the decrease in FM. The multifunctional nature of adiponectin and
its potentially pivotal role in mediating comorbidity risk make it a
worthwhile and relatively inexpensive test to perform; analyses of
high-molecular-weight and low-molecular-weight adiponectin is recommended in all studies (77,78).

Thyroid hormones
Measures of key components of thyroid hormones (thyroid-stimulating hormone, thyroxine (T4), and the free T4 Index) are recommended because of their known role in regulating energy balance.
Diet-induced weight loss is accompanied by a decline in thyroidstimulating hormone, Triidothyronine (T3), and T4 similar to “sick
euthyroid syndrome” (79,80), and thyroid-hormone repletion in
weight-reduced individuals has recently been reported to resolve
some of the peripheral adaptive responses thought to drive weight
regain (Rosenbaum M, Goldsmith R, Haddad F, et al., unpublished
data, 2018) in a manner similar to what is seen following thyroid
repletion in hypothyroid individuals (81,82). Other factors commonly measured when assessing thyroid status (T3, reverse T3)
present a significant burden for researchers because of the expense
of these assays and are suggested only when resources are available.

Hunger/satiety signals
Hunger and/or satiety hormone levels change in response to meals
and collectively provide surrogate signals for nutrient availability. A
number of gut-derived peptides, including ghrelin, GLP-1, and
PYY3-36, affect appetite (83) and coordinately change in response to
calorie restriction (1). Baseline total ghrelin levels are predictive of
weight loss (70), and meal responses of PYY3-36 and GLP-1 have
been associated with successful reduced-weight maintenance (84).
Such studies provide examples of how these peptides could be valuable in modeling treatment outcomes. Though postprandial responses
of these hormones have provided the most pertinent information for
predicting treatment responses, meal challenges were judged as too
great of a burden on both participants and the researchers. The measurement of fasting total ghrelin, GLP-1, and PYY3-36 is recommended for all weight-loss studies as the best compromise between
feasibility and informational value. Other gut peptides with similar
actions were considered for predicting treatment outcomes, including
cholecystokinin and glucagon inhibitory peptide, but the added value
was deemed insufficient because of the greater assay difficulty and
expense and the likelihood of collinearity with those already recommended. Plasma AgRP has been suggested as a biomarker of hypothalamic melanocortin activity, which could reflect downstream
activity of the hunger and satiety signals even though there is only
limited evidence for it as a biomarker. AgRP is linked to insulin
sensitivity during and after weight loss (85), suggesting that this
molecule may provide insights relevant to other biomarkers as well
as brain function. For these reasons, measures of cholecystokinin,
glucagon inhibitory peptide, AgRP, and postprandial responses of all
of these hunger/satiety signals were suggested only when it is feasible and resources are available. It should also be noted that properly
processed and stored samples can be biobanked (see below) for
future analyses if cost limitations are prohibitive in a given study.

Nutrient status
Nutrient-sensing systems in peripheral tissues and in specific regions
of the hypothalamus exist that convey signals of nutrient availability
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for appetite regulation and, therefore, serve as indices of nutrient
status. Fasting levels of glucose, nonesterified fatty acids (NEFA),
and triglycerides (TG) are recommended at baseline, during weight
loss, and after weight loss. Glucose, NEFA, and TG are the primary
nutrients in circulation, and all three respond to calorie-restricted
weight loss (1). TG are also thought to affect the sensitivity of the
brain to peripheral hormones through their effects on blood brain
barrier transport. These metabolites consistently change with dietinduced weight loss in a manner that could elevate appetite (1), and
the assays are relatively inexpensive and commonly used in clinical
research. As with the gut peptides, the measuring postprandial
responses of these molecules is not feasible in all studies. For these
reasons, acquiring postprandial responses in glucose, NEFA, and TG
is suggested only when resources are available.

Metabolic function
Metabolic (anabolic and catabolic) function, insulin sensitivity, and
glucose control (recommended) could serve as mediators or moderators of treatment responses and have been shown to influence patterns
of weight loss and weight-loss maintenance (71,86). Some studies
have suggested that diet macronutrient content may influence weightloss intervention efficacy according to the level of insulin sensitivity
(87). The group recommends that fasting levels of insulin, glucagon,
and glycosylated hemoglobin (HbA1c) be measured before, during,
and after weight loss. Along with the metabolite data, these measures
can be utilized to calculate indices of insulin sensitivity and secretion
(homeostatic model assessment of insulin resistance and homeostatic
model assessment for b-cell function; HOMA-IR, HOMA-b recommended) (88). There was some discussion that an oral glucose tolerance test should also be included to provide a more accurate assessment of glucose control. However, there was insufficient evidence
that the oral glucose tolerance test would provide sufficient added
value over the other surrogate biomarkers of metabolic function for
weight-loss outcomes, and it is suggested only when resources are
available. There are more invasive measures of insulin secretion and
sensitivity (hyperinsulinemic-euglycemic clamp, intravenous glucose
tolerance test, etc.) and more comprehensive measures of key aspects
of metabolic flexibility, but these tests are not feasible for all largescale clinical weight-loss trials.

Inflammation
We also recommend assessment of the inflammatory markers tumor
necrosis factor-alpha, C-reactive protein, and interleukin 6 (IL-6) in
the fasted state before, during, and after weight loss. These inflammatory factors could mediate or moderate the impact of metabolic
dysfunction on treatment outcomes. Tumor necrosis factor-alpha is a
true adipokine and is elevated in obesity (89). C-reactive protein is
made in the liver, largely in response to IL-6, which is produced in
liver and skeletal muscle. These molecules represent three different
sources of inflammatory markers and are all associated with the subsequent risk for type 2 diabetes (90) and cardiovascular disease (91).
By using network modeling that combined biological, gut microbiota, and environmental factors relevant to weight trajectories,
baseline levels of IL-6 and plasma insulin most accurately classified
individuals who did or did not lose weight and maintain weight loss
(92). The global inflammatory status could be assessed by larger
panels, but these biomarkers should be sufficient at present to examine the strength of the link between inflammation and treatment
outcomes.
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Figure 1 Review of selection criteria for different tissues that could be biobanked. Whole blood is clearly the best fit for these criteria,
though other tissues should not be eliminated if available depending upon their relevance to the specific study. Collection costs include creation
of sample aliquots; measured markers include metabolites, nucleotides, and proteins.

Biobanking Tissues
The molecular mechanisms underlying the physiological opposition
to weight loss and reduced weight maintenance (2), and the possibility that they mimic the “preobesity” state in which someone is
genetically and physiologically “at risk” for weight gain, have not
been comprehensively elucidated. A uniform methodology across
weight-loss studies for collecting and storing biological samples to
measure RNA and DNA from cells in the blood as well as exosomal
and free RNAs would provide a valuable resource for interrogating
the molecular underpinnings of weight gain, weight loss, and weight
regain. For reasons discussed below, biobanking of whole blood and
its components (plasma, serum, etc.) with appropriate stabilization
(e.g., protease inhibitors) is recommended as the best balance of feasibility, cost, participant burden, expertise and/or equipment needed
to collect and process the samples, and relevance to weight-loss
physiology.

Whole Blood
Though many different kinds of bodily fluids and tissues can be collected with varying degrees of difficulty, expense, and value (Figure 1),
whole blood gives the greatest advantages for ease and the potential
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amount of relevant information it can provide. Though sample collection is invasive and can be challenging for individuals with obesity, participant burden and the need for expertise to collect whole blood samples is offset by the ability to use samples to interrogate circulating
proteins, metabolites, and noncoding RNAs, which have been identified
as relevant to energy homeostasis or which may one day be identified.
In addition, both red and white cells can be used to examine cellular
processes related to a host of outcomes, including glycosylation,
immune response, and metabolism.

Functional Analysis/Genetic Screening
In addition to the assessment of the biomarkers described above,
both RNA and DNA can be extracted from whole blood for a global
assessment of genomic variation, gene expression, and epigenetic
modification to ultimately allow a uniform characterization of the
contribution of genes across weight-loss studies. This genetic screening would comprise a powerful resource for understanding the
genetic and epigenetic molecular underpinnings of variability in
weight loss. This type of screening is suggested at present because
of resource limitations, but, as its feasibility and cost becomes more
reasonable, we fully expect that it will become a recommended
assessment. The biobanking recommendation of whole blood will
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Whole blood

Metabolite panel (glucose,
NEFA, TG)
Insulin, glucagon
Insulin sensitivity: HOMA-IR,
HOMA-b
Glucose control: HbA1c
IL-6, TNF-alpha, CRP

NA
2
NA
NA
NA

NA
NA
NA

Calculated
Questionnaire
Calculated
Interviewer
Technician

Blood
Blood
Blood

Blood
Blood

Blood
Blood

Blood
Blood

NA
NA

NA
NA

NA
NA

NA

NA

Technician

Blood

NA

Technician

Number
of items

NA
NA

Single blood
draw

1

<5
0

0

5

Administration
time (min)

B

B

B, MA

B, MA

Measurement
schedule

Phlebotomist
Phlebotomist

Phlebotomist
Phlebotomist

Phlebotomist
Phlebotomist

Phlebotomist

Phlebotomist
Phlebotomist
Phlebotomist

Equipment, trained
technician
Equipment, trained
technician

Equations

Equipment, trained
technician

Equipment, trained
technician

Resource
needs

C, L, RCT
C, L, RCT

C, L, RCT
C, L, RCT

C, L, RCT
C, L, RCT

C, L, RCT

C, L, RCT
C, L, RCT
C, L, RCT

C, L

C, L, RCT

C, L
C, L

C, L

C, L, RCT

C, L, RCT

Main
evidence
sourcesa

Buccal, saliva, urine, stool
BDNF, DRB3, FTO,
GNPDA2, LYPLA, MC4R,
MTCH2, MTIF3, NEGR1,
PLIN, RANK, LEP, LEPR

OGTT

T3, rT3
CCK, GIP, AgRP,
postprandial responses of
ghrelin, GLP-1, and PYY

Resting state fMRI; fed
and fasted fMRI

3-minute step test

DLW; VCO2, VO2
(calorimetry)
VCO2, VO2 (calorimetry)
DLW

DXA, MRI, QMRS

Suggested
additional
measures

Italic font indicates objective measure.
Evidence included both weight-related outcomes (e.g., weight loss) and weight-related behaviors (e.g., physical activity).
SA, self-administered; B, baseline; MA, multiple assessments across the trial; F, follow-up; C, cross-sectional; L, longitudinal; RCT, randomized controlled trial; BIS, bioelectrical impedance spectroscopy; DXA, dual
energy x-ray absoprtiometry; MRI, magnetic resonance imaging; QMR, quantitiative magnetic resonance; DLW, doubly labeled water; GLP-1, glucagon-like peptide 1; PYY3-36, peptide YY; TSH, thyroid-stimulating hormone; T4, thyroxine; fT4I, free T4 index; T3, triidothyronine; rT3, reverse T3; CRP, C-reactive protein; IL-6, interleukin-6, TNF, tumor necrosis factor; FM, fat mass; FFM, fat-free mass; HOMA-IR, homeostatic model
assessment of insulin resistance; HOMA-b, homeostatic model assessment for b-cell function; NEFA, nonesterified fatty acids; TG, triglycerides.

Metabolic function
Inflammation
Biobanking tissues
Biobanking
Genetic screening

Metabolic function
Metabolic function

Nutrient status

Height, weight, and BMI;
waist-to-hip ratio; waist
circumference
Anatomic fat storage
Bioelectrical impedance
(FM, FFM, visceral fat)
spectroscopy (BIS)
Expended energy (EE)
REE–Mifflin-St. Jeor equation,
total EE
EE-activity
Physical Activity Level (PAL)
Energy intake (EI)
EI, steady state and change
over time
Cardiorespiratory fitness
Resting heart rate
(CRF)
Brain structure and
function
Blood biomarkers
Energy homeostasis
Adiponectin, leptin, amylin
Thyroid hormones
TSH, T4, fT4I (panel)
Hunger/satiety
Ghrelin, GLP-1, PYY3-36
(panel)

Whole body assessments
Anthropometry

Construct

Measure
type

Logistics

TABLE 1 Selected characteristics of recommended core measures for the ADOPT biological domain
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ensure that tissues will be available to pursue future genetic studies,
even if resources are not immediately available. Sequence variations
in multiple genes have been tied to energy balance and treatment
outcomes in weight-loss studies, which could serve to focus the
analysis. These genes include BDNF, DRB3, FTO, GNPDA2,
LYPLA, MC4R, MTCH2, and MTIF3, while other less-studied genes
(NEGR1, PLIN, and RANK, LEP and LEPR) may also provide relevant information about the variability in treatment response. Studies
demonstrating significant intrapair correlations (r 5 0.75-0.85) in
response to weight-loss interventions among identical twins (93) and
genetic predictors of weight-loss response to various interventions in
large clinical trials (94,95) suggest that different single-nucleotide
polymorphisms (SNPs) may be predictive of the magnitude of
weight loss versus regain depending upon the nature of the intervention and subject population. In the future, the use of array-based
chips with highly informative dense SNP content, including
genome-wide tag SNPs found across diverse world populations and
customizable markers for use in large weight-loss studies, can be
used as a cost-effective means of creating a well-powered cohort of
individuals in which the genetic underpinnings of weight loss can be
examined for multiple traits and outcomes.

Other Tissue Considerations
Biobanking of other tissues is also suggested depending upon
resource availability. Buccal (cheek) cells (suggested) are easy and
inexpensive to collect via cytobrushes, which involves simply swabbing the cheeks and gutters of the mouth to collect sloughed cells.
Both DNA and RNA can be extracted from buccal cells (96), though
there is a limited range and relevance of markers that can be measured (96). Similar limitations are inherent in the use of saliva samples (suggested). Urine and stool samples (suggested) are relatively
easy and inexpensive to obtain, though the relevance of urinary biomarkers to weight loss may be limited. Stool (97) can be used to
examine the gut microbiome, gut absorption, and markers of metabolism. Although transplantation of the microbiome from obese or
lean mice or humans to gnotobiotic (germ-free mice) clearly affects
somatotype, the role of the microbiome as a cause or potential therapeutic target in human obesity is not clearly established (98). Current research in the NIH Human Microbiome Project (HMP) (99)
directly addresses these issues, and investigators are suggested to
contact the NIH directly for microbiome banking information.
Tissue biopsies allow for the unbiased genomic, epigenetic, and proteomic interrogation of key metabolic tissues (skeletal muscle, adipose) involved in the regulation of energy balance. Because of the
burdens placed on subjects and investigators, the collection of specific tissue biopsies is suggested for studies with specific objectives
directed at elucidating molecular mechanisms or generating the evidence as to how these tissues could serve as mediators or moderators of treatment outcomes.

Conclusions
The ADOPT biological domain subgroup was tasked with identifying feasible measures of biological constructs (body composition,
energy homeostasis, brain structure and function, blood biomarkers,
and biobanking tissues) that, when used consistently in weight-loss
trials, could serve to explain the variability in treatment outcomes
and lay the foundation for genetic-, epigenetic-, and genomic-based

S32

Obesity | VOLUME 26 | SUPPLEMENT 2 | APRIL 2018

analyses. Selections (Table 1) were made with the underlying goal
of maximizing the potential to address knowledge gaps in obesity
treatment in conjunction with the other ADOPT domains. It is the
intent of the ADOPT project that these recommendations and suggestions as well as the GEM website will be updated as new information becomes available.
It should be emphasized that the recommended measures are not
always the “gold standard,” but they are the ones that are most feasible across numerous different study sizes and population. When
integrated across studies and with the other ADOPT domains, the
recommended measures will facilitate the development of a large
comprehensive database that could be mined to evaluate, propose,
and implement current and future obesity treatments with maximal
efficacy. The recommended and suggested measures are intended to
augment weight-loss intervention studies rather than replace planned
measures.
The strengths and weaknesses of the ADOPT biological domain are
closely intertwined. The main strength is the practicality of the
measures that can be implemented in most, if not all, studies going
forward at little additional expense and inconvenience to investigators and participants. An additional strength is the intentional malleability of the ADOPT recommendations and suggestions. Regular
modifications of the ADOPT domain manuscripts are anticipated
based on new data and techniques that become available and on
input from the scientific community through the GEM website. The
weaknesses of the recommended and suggested measures are that, to
achieve necessary fiscal and feasibility goals, numerous more sensitive or specific measures are not included. To address these issues,
we would encourage biobanking of serum, plasma, and buffy coats
on as many participants as possible in anticipation of the decreasing
costs and increasing understanding of relevant future assays.O

Acknowledgments
The authors gratefully acknowledge the assistance of Drs. Dympna
Gallagher and Judith Korner at Columbia University Medical Center
for their assistance in clarifying and better delineating some of the
body composition and biomarker measures.
C 2018 The Obesity Society
V

References
1. Maclean P, Bergouignan A, Cornier M, Jackman M. Biology’s response to dieting:
the impetus for weight regain. Amer J Regul Integr Comp Physiol 2011;301:R581R600.
2. Leibel R, Rosenbaum M. Metabolic response to weight perturbation. In: Clement K,
ed. Novel Insights into Adipose Cell Functions, Research and Perspectives in
Endocrine Interactions. Heidelberg: Springer-Verlag; 2010: 121-33.
3. Leibel R, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from
altered body weight. N Eng J Med 1995;332:621-628.
4. Manning S, Pucci A, Carter N, et al. Early postoperative weight loss predicts
maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass. Surg
Endosc 2015;29:1484-1491.
5. Smith S, Prosser W, Donajue D, Morgan M, Anderson C, Shanahan W. Lorcaserin
(APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and
women. Obesity (Silver Spring) 2009;17:494-503.
6. Look AHEAD Research Group; Wadden T, Neiberg R, Wing R, et al. Four-year
weight losses in the Look AHEAD study: factors associated with long-term success.
Obesity (Silver Spring) 2011;19:1987-1998.
7. Schwartz M, Boyko E, Kahn S, Ravussin E, Bogardus C. Reduced insulin secretion:
an independent predictor of body weight gain. J Clin Endocrinol Metab 1995;80:
1571-1576.

www.obesityjournal.org

Supplement

Obesity

THE ADOPT PROJECT
8. MacLean PS, Rothman AJ, Nicastro HL, et al. The Accumulating Data to
Optimally Predict obesity Treatment (ADOPT) Core Measures Project: rationale
and approach. Obesity (Silver Spring) 2018;26(suppl 2):S6-S15.
9. MacLean P, Wing R, Davidson T, et al. NIH working group report: innovative
research to improve maintenance of weight loss. Obesity (Silver Spring) 2015;23:
7-15.
10. Look AHEAD Research Group; Unick J, Beavers D, Jakicic J, et al. Effectiveness
of lifestyle interventions for individuals with severe obesity and type 2 diabetes:
results from the Look AHEAD trial. Diabetes Care 2011;34:2152-2157.
11. Wise E, Felton J, Kligman M. Exponential decay modeling can define parameters
of weight loss trajectory after laparoscopic Roux-en-Y gastric bypass. Am J Surg
2017;9610:31328-31334.
12. Nikolic M, Krulijac I, Kirigin L, et al. Initial weight loss after restrictive bariatric
procedures may predict mid-term weight maintenance: results from a 12 month
pilot trial. Bariatr Surg Pract Patient Care 2015;10:68-73.
13. Look AHEAD Research Group; Unick J, Neiberg R, Hogan P, et al. Weight change
in the first 2 months of a lifestyle intervention predicts weight changes 8 years
later. Obesity (Silver Spring) 2015;23:1353-1356.
14. Hadziabdic M, Mucalo I, Hrabac P, Matic T, Rahelic D, Boziko V. Factors
predictive of drop-out and weight loss success in weight management of obese
patients. J Hum Nutr Diet 2015;28(suppl 2):24-32.
15. Bergman R, Stefanovski D, Buchanan T, et al. A better index of body adiposity.
Obesity (Silver Spring) 2011;19:1083-1089.
16. Wang N, Hikida RS, Staron RS, Simoneau J. Muslce fiber types of women after
resistance training- quantitative ultrastructure and enzyme activity. Pflugers Arch
1993;424:494-502.
17. SK Fried ML, K Karastergiou. Shaping fat distribution: new insights into the
molecular determinants of depot- and sex-dependent adipose biology. Obesity
(Silver Spring) 2015;23:1345-1352.
18. Pouliot M, Despres J, Lemieux S, et al. Waist circumference and abdominal sagittal
diameter: best simple anthropometric indexes of abdominal visceral adipose tissue
accumulation and related cardiovascular risk in men and women. Am J Cardiol
1994;73:460-468.
19. Larsson B, Svarsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G.
Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease
and death: 13 year follow up of participants in the study of men born in 1913. Br
Med J 1984;288:1401-1404.
20. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distibution of
adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of
participants in the population study of women in Gothenburg, Sweden. Br Med J
1984;289:1257-1261.
21. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update.
Physiol Rev 2013;93:359-404.
22. Bosy-Westphal A, Kahlhofer J, Lagerpusch M, Skurk T, Muller M. Deep body
composition phenotyping during weight cycling: relevance to metabolic efficiency
and metabolic risk. Obes Rev 2015;16:36-44.
23. Barreira T, Staiano A, Harrington D, et al. Anthropometric correlates of total body
fat, abdominal adiposity, and cardiovascular disease risk factors in a biracial sample
of men and women. Mayo Clin Proc 2012;87:452-460.
24. Kamel E, McNeill G, Han T, et al. Measurement of abdominal fat by magnetic
resonance imaging, dual-energy X-ray absorptiometry and anthropometry in nonobese men and women. Int J Obes 1999;23:686-692.
25. Ludescher B, Machann J, Eschweiler G, et al. Correlation of fat distribution in whole
body MRI with generally used anthropometric data. Invest Radio 2009;44:712-719.
26. National Health and Nutrition Examination Survey (NHANES). National Center for
Health Statistics (NCHS) anthropometry procedures manual. http://wwwcdcgov/nchs/
data/nhanes/nhanes_11_12/Anthropometry_Procedures_Manual.pdf. Published 2011.
27. Ma W, Yang C, Shih S, et al. Measurement of waist cirucmference: midabdominal
or iliac crest? Diabetes Care 2013;36:1660-1666.
28. Shuster A, Patlas M, Pinthus J, Mourtzakis M. The clinical importance of visceral
adiposity: a critical review of methods for visceral adipose tissue analysis. Br J
Radiol 2012;85:1-10.
29. Eastwood S, Tillin T, Dehbi H, et al. Ethnic differences in associations between fat
deposition and incident diabetes and underlying mechanisms: the SABRE study.
Obesity (Silver Spring) 2015;23:699-706.
30. Gibson A, Holmes J, Desautels R, Edmonds L, Nuudi L. Ability of new octapolar
bioimpedance spectroscopy analyzers to predict 4-component-model percentage
body fat in Hispanic, black, and white adults. Amer J Clin Nutr 2008;87:332-338.
31. Finch P. Intra-abdominal fat: comparison of computed tomography fat segmentation
and bioimpedance spectroscopy. Malawi Med J 2017;29:155-159.
32. Thomas E, Collins A, McCarthy J, Fitzpatrick J, Durighel G, Goldston A, Bell J.
Estimation of abdominal fat compartments by bioelectrical impedance: the validity
of the ViScan measurement system in comparison with MRI. Eur J Clin Nutr 2010;
64:523-533.
33. Berstad P, Randby A, Ekeland G, Ulveland H. Body fat and fat-free mass measured
by bioelectric impedance spectroscopy and dual-energy X-ray absorptiometry in
obese and non-obese adults. Br J Nutr 2012;28:1192-1200.

www.obesityjournal.org

34. Phelan S, Wing R. Prevalence of successful weight loss. Arch Int Med 2005;165:
2430. doi: 10.1001/archinte.165.20.2430-a
35. Donahoo W, Levine J, Melanson E. Variability in energy expenditure and its
components. Curr Opin Nutr Metab Care 2004;7:599-605.
36. Hopkins M, Gibbons C, Caudwell P, et al. The adaptive metabolic response to
exercise-induced weight loss influences both energy expenditure and energy intake.
Eur J Clin Nutr 2014;68:581-586.
37. Thomas D, Redman CML, Heymsfield S, et al. Effect of dietary adherence on the
body weight plateau: a mathematical model incorporating intermittent compliance
with energy intake prescription. Am J Clin Nutr 2014;100:787-795.
38. Hills A, Mokhtar N, Byrne N. Assessment of physical activity and energy
expenditure: an overview of objective measures. Front Nutr 2014;1:5. doi: 10.1001/
archinte.165.20.2430-a
39. Mifflin M, St. Jeor S, Hill L, Scott B, Daugherty S, Koh Y. A new predictive
equation for resting energy expenditure in healthy individuals. Am J Clin Nutr
1990;51:241-247.
40. Schusdziarra V, Wolfschlager K, Hausmann M, Wagenpfell S, Erdman J. Accuracy
of resting energy expenditure calculations in unselected overweight and obese
patients. Ann Nutr Metab 2014;65:299-309.
41. Valencak T, Osterrieder A, Schulz T. Sex matters: the effects of biological sex on
adipose tissue biology and energy metabolism. Redox Biol 2017;12:806-813.
42. Johansson G, Westerterp K. Assessment of the physical activity level with two
questions: validation with doubly labeled water. Int J Obes 2008;32:1031-1033.
43. Rosenbaum M, Ravussin E, Matthews D, et al. A comparative study of different
means of assessing long-term energy expenditure in humans. Amer J Physiol 1996;
270:R496-R504.
44. Madden A, Parker L, Amirabdollahian F. Accuracy and preference of measuring
resting energy expenditure using a handheld calorimeter in healthy adults. J Hum
Nutr Diet 2013;26:587-595.
45. Bucholz A, Schoeller D. Is a calorie a calorie. Am J Clin Nutr 2004;79:899S-906S.
46. Beavers K, Ambrosius W, Rejeski W, et al. Effect of exercise type during
intentional weight loss on body composition in older adults with obesity. Obesity
(Silver Spring) 2016;25:1823-1829.
47. Schoeller D. How accurate is self-reported dietary energy intake ? Nutr Rev 1990;
48:373-379.
48. Sanghvi A, Redman L, Martin C, Ravussin E, Hall K. Validation of an inexpensive
and accurate mathematical method to measure long-term changes in free-living
energy intake. Am J Clin Nutr 2015;102:353-358.
49. Racette S, Das S, Bhapkar M, et al; CALERIE Study Group. Approaches for
quantifying energy intake and %calorie restriction during calorie restriction
interventions in humans: the multicenter CALERIE study. Am J Physiol Endocrinol
Metab 2012;302:E441-E448.
50. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an
independent predictor of the reduction in liver fat during a lifestyle intervention in
non-alcoholic fatty liver disease. Gut 2009;58:1281-1288.
51. Gaesser G, Tucker W, Jarrett C, Angadi S. Fitness versus fatness: which influences
health and mortality risk the most? Curr Sports Med Rep 2015;14:327-332.
52. Jucra R, Jackson A, Lamonte M, et al. Assessing cardiorespiratory fitness without
performing exercise testing. Am J Prev Med 2005;29:185-193.
53. Bennett H, Parfitt G, Davison K, Eston R. Validity of submaximal step tests to
esitmate maximal oxygen uptake in healthy adults. Sports Med 2016;46:737-750.
54. Shephard R, Bailey D, Mirwald R. Development of the Canadian Home Fitness
Test. Can Med Assoc J 1976;114:675-679.
55. Simonsick E, Fan E, Fleg J. Estimating cardiorespiratory fitness in well-functioning
older adults: treadmill validation of the long distance corridor walk. J Am Geriatr
Soc 2006;54:127-132.
56. Windham BG, Lirette ST, Fornage M, et al. Associations of brain structure with
adiposity and changes in adiposity in a middle-aged and older biracial population.
J Gerontol A Biol Med Sci 2017;72:825-831.
57. Contrera-Rodriguez O, Martin-Perez C, Vilar-Lopez R, Verdejo-Garcia A. Ventral
and dorsal striatum networs in obesity: link to food craving and weight gain. Biol
Psychiatr 2017;81:789-796.
58. Papegeorgiou I, Astrakas L, Xydis N, et al. Abnormalities of brain neural circuits
related to obesity: a Diffusion Tensor Imaging study. Magn Reson Imag 2017;37:
116-121.
59. Horstmann A. It wasn’t me; it was my brain--obesity associated characteristics of
brain circuits govening decision making. Physiol Behav 2017;176:125-133.
60. Figleyu C, Asem J, Levenbaum E, Courtney S. Effects of body mass index and
body fat percent on default mode, executive control, and salience network structure
and function. Front Neurosci 2016;10:234. doi: 10.3389/fnins.2016.00234
61. Sutin AR, Boutelle K, Czajkowski SM, et al. Accumulating Data to Optimally
Predict obesity Treatment (ADOPT) Core Measures: psychosocial domain. Obesity
(Silver Spring) 2018;26(suppl 2):S45-S54.
62. Drysdale A, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers
define neurophysiological subtypes of depression. Nat Med 2017;23:28-38.

Obesity | VOLUME 26 | SUPPLEMENT 2 | APRIL 2018

S33

Obesity

ADOPT: Biological Domain Rosenbaum et al.

63. Park B, Seo J, Park H. Functional brain networks associated with eating behaviors
in obesity. Sci Rep 2016;31:23891. doi: 10.1038/srep23891
64. Wright H, Xiaoyun L, Fallon N, et al. Differential effects of hunger and satiety on
insular cortex and hypothalamic functional connectivity. Eur J Neurosci 2016;43:
1181-1189.
65. Garcia-Garcia I, Jurado M, Garolera M, et al. Alterations of the salience network in
obesity: a resting state MRI study. Hum Brain Mapp 2013;34:2788-2797.
66. Kullmann S, Heni M, Velt R, et al. The obese brain: association of body mass
index and insulin sensitivity with resting state network functional connectivity. Hum
Brain Mapp 2012;33:1052-1061.
67. Chen S, Dong D, Jackson T, Zhuang Q, Chen H. Trait-based food cravings are
encoded by regional homogeneity in the parahippocampal gyrus. Appetite 2017;114:
115-160.
68. Action in Health in Diabetes Brain Magnetic Resonance Imaging Look AHEAD
Brain Ancillary Study Research Group; Casanova R, Hayasaka S, Saldana S, et al.
Relative differences in resting-state brain connectivity associated with long term
intensive lifestyle intervention. Psychoneuroendocrinol 2016;74:231-239.
69. Lepping R, Bruce A, Grancisco A, et al. Resting state brain connectivity after
surgical and behavioral weight loss. Obesity (Silver Spring) 2015;23:1422-1428.
70. Crujeiras A, Goyenechea E, Abete I, et al. Weight regain after a diet-induced loss
is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin
Endocrinol Metab 2010;95:5037-5044.
71. Courcoulas A, Christian M, O’Rourke R, et al. Preoperative factors and 3-year
weight change in the Longitudinal Assessment of Bariatric Surgery (LABS)
consortium. Surg Obes Relat Dis 2015;11:1109-1118.
72. Strohacker K, McCaffery J, MacLean P, Wing R. Adaptations of leptin, ghrelin, or
insulin during weight loss as predictors of weight regain: a review of current
literature. Int J Obes 2014;38:388-396.
73. Rosenbaum M, Leibel R. 20 years of leptin: role of leptin in energy homeostasis in
humans. J Endocrinol 2014;223:T83-T96.
74. Boyle C, Lutz T, Le Foll C. Amylin–Its role in the homeostatic and hedonic control
of eating and recent developments of amylin analogs to treat obesity. Mol Metab
2017;8:203-210.
75. Hay D, Chen S, Lutz T, Parkes D, Roth J. Amylin: pharmacology, physiology, and
clinical potential. Pharmacol Rev 2015;67:564-600.
76. Ravussin E, Smith S, Mitchell J, et al. Enhanced weight loss with pramlintide/
metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
Obesity (Silver Spring) 2009;17:1736-1743.
77. Achari A, Jain S. Adiponectin, a therapuetic target for obesity, diabetes, and
endothelial dysfunction. Int J Mol Sci 2017;18:e1321. doi: 10.3390/ijms18061321
78. Sahin-Efe A, Katsikeris F, Matzoros C. Advances in adipokines. Metabolism 2012;
61:1659-1665.
79. Rosenbaum M, Hirsch J, Murphy E, Leibel R. The effects of changes in body
weight on carbohydrate metabolism, catecholamine excretion, and thyroid function.
Amer J Clin Nutr 2000;71:1421-1432.
80. Sumithran P, Prendergast L, Delbridge E, et al. Long-term persistance of hormonal
adaptations to weight loss. N Eng J Med 2011;365:1597-604.
81. Caiozzo V, Baker M, Baldwin K. Novel transitions in MHC isoforms: separate and
combined effects of thyroid hormone and mechanical unloading. J Appl Physiol
1998;85:2237-2248.
82. Canepari M, Cappelli V, Pellegrino M, Zanardi M, Reggiani C. Thyroid hormone
regulation of MHC isoform composition and myofibrillar ATPase activity in rat
skeletal muscles. Arch Physiol Biochem 1998;106:308-315.

S34

Obesity | VOLUME 26 | SUPPLEMENT 2 | APRIL 2018

83. Monteiro M, Batterham R. The importance of the gastrointestingal tract in controlling
food intake and regulating energy balance. Gastroenterol 2017;152:1707-1717.
84. Iepsen I, Lundgren J, Holst J, Madsbad S, Torekov S. Succesful weight loss
maintenance includes long-term increased meal responses to GLP-1 and PYY3-36.
Eur J Endocrinol 2016;174:775-784.
85. Page-Wilson G, Nguyen K, Atalayer D, et al. Evaluation of CSF and plasma
biomarkers of brain melanocortin activity in response to caloric restriction in
humans. Am J Phyiol Endocrinol Metab 2017;312:E19-E26.
86. Look AHEAD Study Group; Espeland M, Bray G, Neiberg R, et al. Describing
patterns of weight changes using principal components analysis: results from the
Action for Health in Diabetes (Look AHEAD) research group. Ann Epidemiol 2009;
19:701-710.
87. Cornier M, Donahoo W, Pereira R, et al. Insulin sensitivity determines the
effectiveness of dietary macronutrient composition on weight loss in obese women.
Obes Res 2005;13:703-709.
88. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treatcher DF, Turner RC.
Homeostasis model assessmet: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:
412-419.
89. Moller K, Ostermann AI, Rund K, et al. Influence of weight reduction on
blood levels of C-reactive protein, tumor necrosis factor-a, interleukin-6, and
oxylipins in obese subjects. Prostaglandins Leukot Essent Fatty Acids 2016;
106:39-49.
90. Rubin D, McMurray R, Harrell J, Hackney A, Thorpe D, Hagg A. The association
between insulin resistance and cytokines in adolescents: the role of weight status
and exercise. Metabolism 2008;57:683-690.
91. Espinola-Klein C, Gori T, Blankenberg S, Munzie T. Inflammatory markers and
cardiovascular disease risk in the metabolic syndrome. Front Biosci 2011;16:16631674.
92. Kong L, Wuillemin P, Bastard J, et al. Insulin resistance and inflammation predict
kinetic body weight changes in response to dietary weight loss and maintenance in
overweight and obese subjects by using a Bayesian network approach. Amer J Clin
Nutr 2013;98:1385-1394.
93. Hainer V, Stunkard A, Kunesova M, Parizkova J, Stitch V, Allison D. A twin study
of weight loss and metabolic efficiency. Int J Obes 2001;25:533-537.
94. Diabetes Prevention Program Research Group; Delahanty L, Pan Q, Jablonski K,
et al. Genetic predictors of weight loss and weight regain after intensive lifestyle
modification, metformin treatment, or standard care in the Diabetes Prevention
Program. Diabetes Care 2012;35:363-366.
95. The Genetic Subgroup of Look AHEAD and The Look AHEAD Research Group;
McCaffery J, Papandonatos G, Huggins G, et al. Human cardiovascular disase IBC
chip-wide association with weight loss and weight regain in the Look AHEAD trial.
Hum Hered 2013;75:160-174.
96. Hansen T, Simonsen M, Nielsen F, Hundrup Y. Collection of blood, saliva, and
buccal cell samples in a pilot study on the Danish nurse cohort: comparison of the
response rate and quality of genomic DNA. Cancer Epidemiol Biomarkers Prev
2007;15:2072-2076.
97. Vandenputte D, Tito R, Vanleeuwen R, Falony G, Raes J. Practical considerations
for large-scale gut microbiome studies. FEMS Microbiol Rev 2017;41(suppl 1):
S154-S167.
98. Rosenbaum M, Knight R, Leibel R. The microbiome in human obesity. Trends
Endocrinol Metab 2015;26:493-501.
99. The NIH HMP Working Group; Peterson J, Garges S, Giovanni M, et al. THe NIH
Human Microbiome Project. Genom Res 2009;19:2317-2323.

www.obesityjournal.org

